» Articles » PMID: 12196370

Specific Codon 13 K-ras Mutations Are Predictive of Clinical Outcome in Colorectal Cancer Patients, Whereas Codon 12 K-ras Mutations Are Associated with Mucinous Histotype

Overview
Journal Ann Oncol
Publisher Elsevier
Specialty Oncology
Date 2002 Aug 28
PMID 12196370
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Background: K-ras mutations, one of the earliest events observed in colorectal carcinogenesis, are mostly found in codons 12 and 13, and less frequently in codon 61, all three of which are estimated to be critical for the biological activity of the protein. Nevertheless the prognostic significance of such mutations remains controversial. Our purpose was to assess whether any or specific K-ras mutations in primary colorectal cancer had prognostic significance and were linked to clinico-pathological parameters.

Patients And Methods: Paired tumor and normal tissue samples from a consecutive series of 160 untreated patients (median of follow up 71 months), undergoing resective surgery for primary colorectal carcinoma, were prospectively studied for K-ras mutations by PCR/single strand conformation polymorphism sequencing.

Results: Seventy-four of the 160 (46%) primary colorectal carcinomas presented mutations in K-ras: 54% in codon 12, 42% in codon 13 (particularly G-->A transition) and 4% in both. Codon 12 K-ras mutations were associated with mucinous histotype (P <0.01), while codon 13 K-ras mutations were associated with advanced Dukes' stage (P <0.05), lymph-node metastasis (P <0.05) and high S-phase fraction (P <0.05). Multivariate analysis showed that codon 13 K-ras mutations, but not any mutation, were independently related to risk of relapse or death.

Conclusions: Our results suggest that codon 12 K-ras mutations may have a role in the mucinous differentiation pathway, while codon 13 mutations have biological relevance in terms of colorectal cancer clinical outcome.

Citing Articles

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.


The Abundance of KRAS and RAS Gene Mutations in Cancer.

Stites E Methods Mol Biol. 2024; 2797:13-22.

PMID: 38570449 DOI: 10.1007/978-1-0716-3822-4_2.


A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and Colorectal Cancers-Specimens of Low Tumor Percentage Should Be Analyzed with Caution.

Zarabi S, Zhai L, Cheng Y Biomolecules. 2024; 14(2).

PMID: 38397405 PMC: 10887151. DOI: 10.3390/biom14020168.


Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?.

Contreras-Toledo D, Jimenez-Fonseca P, Lopez Lopez C, Fernandez Montes A, Lopez Munoz A, Vazquez Rivera F Br J Cancer. 2024; 130(5):777-787.

PMID: 38191609 PMC: 10912758. DOI: 10.1038/s41416-023-02563-w.


Evaluating distinct KRAS subtypes as potential biomarkers for immune checkpoint inhibitor efficacy in lung adenocarcinoma.

Wang Q, Tang Z, Li C, Li X, Su C Front Immunol. 2023; 14:1297588.

PMID: 37954616 PMC: 10635421. DOI: 10.3389/fimmu.2023.1297588.